
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
Take this MedPage Today survey.
On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.






